Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
Valuation and Earnings
This table compares Qualigen Therapeutics and Unicycive Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Qualigen Therapeutics | N/A | N/A | -$6.26 million | ($7.50) | -0.36 |
| Unicycive Therapeutics | $680,000.00 | 186.46 | -$36.73 million | ($3.95) | -1.49 |
Profitability
This table compares Qualigen Therapeutics and Unicycive Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Qualigen Therapeutics | N/A | N/A | -202.16% |
| Unicycive Therapeutics | N/A | -227.32% | -117.71% |
Volatility & Risk
Qualigen Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Qualigen Therapeutics and Unicycive Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Qualigen Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Unicycive Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
Unicycive Therapeutics has a consensus price target of $34.33, indicating a potential upside of 481.92%. Given Unicycive Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Unicycive Therapeutics is more favorable than Qualigen Therapeutics.
Institutional & Insider Ownership
3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 10.7% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Unicycive Therapeutics beats Qualigen Therapeutics on 9 of the 12 factors compared between the two stocks.
About Qualigen Therapeutics
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
About Unicycive Therapeutics
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
